Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Pratley

Showing results (1-10 of 267) with videos related to

Pageof 27
Sort By:
Diabetes Care|July 1, 2010
GIP: an inconsequential incretin or not?Richard E Pratley
Expert Opinion on Pharmacotherapy|February 5, 2009
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesRichard E Pratley
Current Diabetes Reports|March 14, 2007
Metabolic syndrome: why the controversy?Richard E Pratley
The American Journal of Medicine|August 20, 2013
Type 2 diabetes is one of the leading causes of premature morbidity and mortality. IntroductionRichard E Pratley
The Diabetes Educator|February 17, 2009
Expanding treatment options for type 2 diabetes: the old and the newRichard E Pratley
Clinical Interventions in Aging|August 2, 2014
Linagliptin use in older individuals with type 2 diabetesRichard E Pratley
Medscape Journal of Medicine|September 5, 2008
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetesRichard E Pratley
Current Diabetes Reports|July 29, 2004
The quality of fat in the diet and its impact on insulin sensitivityRichard E Pratley
The American Journal of Medicine|August 20, 2013
The early treatment of type 2 diabetesRichard E Pratley
Diabetologia|May 23, 2014
The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?Richard E Pratley
Pageof 27

Showing results (1-10 of 267) with videos related to

Sort By:
Pageof 27
Diabetes Care|July 1, 2010
GIP: an inconsequential incretin or not?Richard E Pratley
Expert Opinion on Pharmacotherapy|February 5, 2009
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesRichard E Pratley
Current Diabetes Reports|March 14, 2007
Metabolic syndrome: why the controversy?Richard E Pratley
The American Journal of Medicine|August 20, 2013
Type 2 diabetes is one of the leading causes of premature morbidity and mortality. IntroductionRichard E Pratley
The Diabetes Educator|February 17, 2009
Expanding treatment options for type 2 diabetes: the old and the newRichard E Pratley
Clinical Interventions in Aging|August 2, 2014
Linagliptin use in older individuals with type 2 diabetesRichard E Pratley
Medscape Journal of Medicine|September 5, 2008
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetesRichard E Pratley
Current Diabetes Reports|July 29, 2004
The quality of fat in the diet and its impact on insulin sensitivityRichard E Pratley
The American Journal of Medicine|August 20, 2013
The early treatment of type 2 diabetesRichard E Pratley
Diabetologia|May 23, 2014
The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?Richard E Pratley
Pageof 27